NeuroSearch, Glaxo start Phase II studies of NS2359 depression
Forbes - COPENHAGEN (AFX) - NeuroSearch AS said it and GlaxoSmithKline PLC (GSK) have started Phase II clinical development of drug candidate NS2359 (GSK372475) in patients diagnosed with major depressive disorder. Under a development and licensing agreement
Source: www.forbes.com
Depression Related News
KOLD-TV - The physical examination will either diagnosis and/or rule out any medical conditions (such as thyroid disease, cancers or neurologic diseases) that could be causing the depression. Treatment Treatment usually involves medication, psychotherapy or a
Source: www.kold.com
Exclusive Reports
San Jose Business Journal - New leadership, new location for Parkinson's Institute Conflict of interest questions dog Reed's choice for budget czar Impact of patent ruling likely to extend far into tech sphere Corcept hopeful third test will clear depression treatment Buying
Source: sanjose.bizjournals.com
Chronic brain syndrome; Lewy body dementia; DLB; Vascular dementia?
Kansas City Channel - Such conditions include heart failure , decreased oxygen ( hypoxia ), thyroid disorders , anemia , nutritional disorders, infections, and psychiatric conditions such as depression. Treatment of co-existing medical and
Source: www.thekansascitychannel.com
Clarification: Dec. 28 Cyberonics Story
MSN MoneyCentral - Additionally, the company could soon face competition from newer depression-treatment devices. Cyberonics will brief a panel of medical experts on two follow-up studies at an FDA meeting on Jan. 26. The agency posted details about the meeting Tuesday
Source: news.moneycentral.msn.com
Click here for more information about elderly depression elderly depression
<< Home